[ET Net News Agency, 18 January 2022] Luye Pharma Group Ltd. (02186) said the marketing
authorization application for the group's analgesic product under development, oxycodone
and naloxone extended-release tablets (LY021702), has been accepted by the Centre for Drug
Evaluation of the National Medical Products Administration in the People's Republic of
China.
LY021702 is the first oxycodone and naloxone extended release tablet product that has
high technical barriers developed by a Chinese company. It consists of oxycodone
hydrochloride, a strong opioid receptor agonist, and naloxone hydrochloride, an opioid
antagonist, for the treatment of moderate to severe chronic pain that cannot be
effectively controlled by non-opioids, with pain relief lasting up to 12 hours. It has a
deterrent feature regarding opioid abuse and can relieve gastrointestinal adverse effects
such as opioid-induced constipation. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02186 LUYE PHARMA
Nominal 
2.720 +0.020 (+0.741%) Others
18/01/2022 13:55
Luye Pharma (02186) gets application accepted
| Remark: | Real time quote last updated: 26/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |